These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 23953245)
1. New developments in the medical management of overactive bladder. Robinson D; Giarenis I; Cardozo L Maturitas; 2013 Nov; 76(3):225-9. PubMed ID: 23953245 [TBL] [Abstract][Full Text] [Related]
3. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy. Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944 [TBL] [Abstract][Full Text] [Related]
4. The medical management of refractory overactive bladder. Robinson D; Giarenis I; Cardozo L Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402 [TBL] [Abstract][Full Text] [Related]
5. A drug safety evaluation of mirabegron in the management of overactive bladder. Robinson D; Thiagamoorthy G; Cardozo L Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445 [TBL] [Abstract][Full Text] [Related]
6. The management of overactive bladder refractory to medical therapy. Robinson D; Giarenis I; Cardozo L Maturitas; 2013 May; 75(1):101-4. PubMed ID: 23415926 [TBL] [Abstract][Full Text] [Related]
13. Mirabegron for overactive bladder syndrome. Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821 [TBL] [Abstract][Full Text] [Related]
14. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995 [TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668 [TBL] [Abstract][Full Text] [Related]
16. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
17. Understanding the elements of overactive bladder: questions raised by the EPIC study. Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K; BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602 [TBL] [Abstract][Full Text] [Related]
18. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
19. The pharmacotherapy of overactive bladder. Athanasopoulos A Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348 [TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. Cardozo L; Thorpe A; Warner J; Sidhu M BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]